Jane Street
SKYE icon

Jane Street’s Skye Bioscience SKYE Stock Holding History

Jane Street’s Portfolio SKYE Stock Details SKYE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-15,100
Closed -$59.3K – 12636
2025
Q3 		$59.3K Sell
15,100
-3,300
-18% -$12.5K ﹤0.01% 10297
2025
Q2 		$76.9K Buy
+18,400
New +$38.1K ﹤0.01% 9062

Other funds holding SKYE

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Jane Street's SKYE Position: Q1 2026 in Review

Jane Street sold out of Skye Bioscience (SKYE) in Q1 2026, closing a stake of 24,615 shares — an estimated $18.5K sold.

Jane Street first reported a position in SKYE in Q3 2024 and held it in 4 quarters. The position peaked at $102K in Q4 2024. 39 funds tracked by Wall St. Rank hold SKYE as of Q1 2026.

  • Jane Street reported no remaining Skye Bioscience position as of Q1 2026 after selling out during the quarter.
  • Jane Street sold 24,615 Skye Bioscience shares in Q1 2026, an estimated $18.5K.
  • Jane Street first reported a position in Skye Bioscience in Q3 2024 and held it in 4 quarters.
  • Jane Street's Skye Bioscience position peaked at $102K in Q4 2024.
  • 39 funds tracked by Wall St. Rank held Skye Bioscience as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.